Zevra Therapeutics annual debt-to-equity ratio
2021
2022
2023
2024
2025
Zevra Therapeutics Debt-to-Equity Ratio Growth & History (ZVRA)
Zevra Therapeutics's debt-to-equity ratio was 0.41 for fiscal 2025.
View full Zevra Therapeutics company overviewZevra Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.41 | −1.11 | −73.11% |
| 2024 | 2024-12-31 | 1.52 | 1.42 | +1450.52% |
| 2023 | 2023-12-31 | 0.10 | 0.08 | +454.14% |
| 2022 | 2022-12-31 | 0.02 | 0.00 | +11.78% |
| 2021 | 2021-12-31 | 0.02 | — | — |
Zevra Therapeutics quarterly debt-to-equity ratio
Q2.15
Q2.16
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.01 | −0.52 | −98.71% |
| Q1 2026 | 2026-03-31 | 0.01 | −1.50 | −99.63% |
| Q4 2025 | 2025-12-31 | 0.41 | −1.11 | −73.11% |
| Q3 2025 | 2025-09-30 | 0.47 | −0.39 | −45.17% |
| Q2 2025 | 2025-06-30 | 0.53 | −1.30 | −70.99% |
| Q1 2025 | 2025-03-31 | 1.51 | 1.48 | +5613.27% |
| Q4 2024 | 2024-12-31 | 1.52 | 1.42 | +1450.52% |
| Q3 2024 | 2024-09-30 | 0.86 | 0.84 | +5450.69% |
| Q2 2024 | 2024-06-30 | 1.83 | 1.81 | +9826.14% |
| Q1 2024 | 2024-03-31 | 0.03 | 0.01 | +29.12% |
| Q4 2023 | 2023-12-31 | 0.10 | 0.08 | +454.14% |
| Q3 2023 | 2023-09-30 | 0.02 | 0.00 | +0.93% |
| Q2 2023 | 2023-06-30 | 0.02 | 0.00 | +17.26% |
| Q1 2023 | 2023-03-31 | 0.02 | 0.01 | +64.30% |
| Q4 2022 | 2022-12-31 | 0.02 | 0.00 | +11.78% |
| Q3 2022 | 2022-09-30 | 0.02 | 0.00 | +17.97% |
| Q2 2022 | 2022-06-30 | 0.02 | 0.00 | +13.12% |
| Q1 2022 | 2022-03-31 | 0.01 | −0.01 | −46.79% |
| Q4 2021 | 2021-12-31 | 0.02 | — | — |
| Q3 2021 | 2021-09-30 | 0.01 | — | — |
| Q2 2021 | 2021-06-30 | 0.01 | — | — |
| Q1 2021 | 2021-03-31 | 0.02 | — | — |
| Q2 2016 | 2016-06-30 | 6.11 | 6.10 | +49115.76% |
| Q2 2015 | 2015-06-30 | 0.01 | — | — |
Zevra Therapeutics debt-to-equity ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Zevra Therapeutics's debt-to-equity ratio increased from 0.02 to 0.41, a change of 0.39. The latest reported quarter, Q2 2026, shows 0.01.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zevra Therapeutics source filings ↗